Abstract
Introduction: The lifetime prevalence of post-traumatic stress disorder (PTSD) is estimated to be 7.3% in the U.S. population, 10-20% among active duty service members and 35-40% among veterans. Overall success rates of evidence-based therapies for PTSD are low, leading clinicians to explore new therapeutic options. This study evaluated all published articles on the use of stellate ganglion block (SGB) as an adjunctive therapy for treatmentrefractory PTSD. Methods: EMBASE, PubMed, PsychINFO and Cochrane databases were searched using keyword combinations including stellate ganglion block, SGB, post-traumatic stress disorder, and PTSD. Articles were restricted to English language with no date delimiter. Twelve publications were identified, seven of which were eliminated due to lack of case data, duplicate patient sample, or descriptive reports with no standardized PTSD symptom assessment. Twenty-four cases from five articles were examined further by two independent evaluators who extracted data on sociodemographic and clinical characteristics including PTSD symptoms, comorbidities, and treatment history. Interrater reliability showed complete agreement (κ=1.0). Results: Cases were predominantly male (n=21, 88%) and active duty military (n=14, 58%) or veterans (n=8, 33%) with combat-related PTSD. The average age was 40.5 years (±10.0 SD). All cases had received >1 year of psychotherapy and pharmacotherapy before SGB. Seventeen cases (71%) received one SGB, seven (29%) received multiple SGBs. Clinically meaningful improvements were observed in 75% (n=18) of cases after SGB, with significant differences in mean PTSD scores pre- (69.5 ± 26.6) and post-SGB (34.2 ± 32.5) across cases (p<0.001). The effect size was relatively large (d=1.2). On average, PTSD improved by 50.4% (± 30.9 SD; range: 6.3-98.4) for cases with one SGB and 69.0% (± 28.0 SD; range: 9.2-93.5) for cases with multiple SGBs. Conclusions: Most patients with treatment-refractory PTSD experienced rapid improvement after SGB. Robust clinical trials are needed to determine SGB’s treatment efficacy for PTSD.
Highlights
The lifetime prevalence of post-traumatic stress disorder (PTSD) is estimated to be 7.3% in the U.S population, 10-20% among active duty service members and 35-40% among veterans
Another emerging use of stellate ganglion block (SGB) as a potentially beneficial treatment for psychiatric conditions has been in post-traumatic stress disorder (PTSD) [4]
The purpose of this review was to examine all published cases on the use of SGB treatment for treatment-refractory PTSD in order to comprehensively evaluate its impact on PTSD symptom improvement
Summary
The lifetime prevalence of post-traumatic stress disorder (PTSD) is estimated to be 7.3% in the U.S population, 10-20% among active duty service members and 35-40% among veterans. SGB has been shown to be helpful in the treatment of hallucinations in schizophrenia [2] and climacteric psychosis [3] Another emerging use of SGB as a potentially beneficial treatment for psychiatric conditions has been in post-traumatic stress disorder (PTSD) [4]. Many earlier names for the condition, such as “shell shock” or “combat fatigue”, emphasized war as a cause of the syndrome, and an estimated 10-20% of active duty service members and 35-40% of veterans do experience PTSD [5,6]. Familiar symptoms of PTSD include nightmares, flashbacks, exaggerated startle, emotional numbing, and an inability or unwillingness to engage in activities that remind the individual of the trauma [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
